Aviva’s Intuitive Surgical ISRG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$141M Buy
306,437
+8,778
+3% +$4.44M 0.24% 76
2025
Q4
$169M Buy
297,659
+15,346
+5% +$8.17M 0.28% 65
2025
Q3
$126M Buy
282,313
+17,048
+6% +$8.18M 0.23% 86
2025
Q2
$144M Buy
265,265
+16,547
+7% +$8.65M 0.3% 60
2025
Q1
$123M Buy
248,718
+34,642
+16% +$19.2M 0.3% 64
2024
Q4
$112M Buy
214,076
+55,802
+35% +$29.1M 0.29% 63
2024
Q3
$77.8M Buy
158,274
+13,863
+10% +$6.45M 0.2% 108
2024
Q2
$64.2M Buy
144,411
+25,264
+21% +$10.1M 0.18% 112
2024
Q1
$47.6M Buy
119,147
+6,162
+5% +$2.33M 0.16% 127
2023
Q4
$38.1M Buy
112,985
+11,002
+11% +$3.28M 0.14% 168
2023
Q3
$29.8M Sell
101,983
-14,273
-12% -$4.46M 0.13% 190
2023
Q2
$39.8M Sell
116,256
-50,324
-30% -$15.2M 0.16% 124
2023
Q1
$42.6M Sell
166,580
-14,411
-8% -$3.55M 0.19% 121
2022
Q4
$48M Buy
180,991
+32,582
+22% +$7.94M 0.24% 87
2022
Q3
$27.8M Buy
148,409
+26,314
+22% +$5.65M 0.16% 145
2022
Q2
$24.5M Buy
122,095
+24,527
+25% +$5.75M 0.13% 194
2022
Q1
$29.4M Sell
97,568
-12,009
-11% -$3.51M 0.15% 147
2021
Q4
$39.4M Sell
109,577
-1,852
-2% -$637K 0.17% 130
2021
Q3
$36.9M Sell
111,429
-8,058
-7% -$2.71M 0.16% 134
2021
Q2
$36.6M Buy
119,487
+258
+0.2% +$72.4K 0.16% 136
2021
Q1
$29.4M Buy
119,229
+42
+0% +$10.6K 0.14% 148
2020
Q4
$32.5M Buy
119,187
+4,005
+3% +$994K 0.17% 120
2020
Q3
$27.2M Sell
115,182
-3,591
-3% -$806K 0.16% 114
2020
Q2
$22.6M Sell
118,773
-2,127
-2% -$381K 0.14% 128
2020
Q1
$20M Buy
120,900
+111
+0.1% +$20.3K 0.15% 130
2019
Q4
$23.8M Sell
120,789
-603
-0.5% -$113K 0.14% 139
2019
Q3
$21.8M Sell
121,392
-5,160
-4% -$892K 0.15% 139
2019
Q2
$22.1M Sell
126,552
-2,334
-2% -$400K 0.15% 140
2019
Q1
$24.5M Buy
128,886
+1,551
+1% +$276K 0.16% 133
2018
Q4
$20.3M Sell
127,335
-36,252
-22% -$6.14M 0.15% 144
2018
Q3
$31.3M Sell
163,587
-6,324
-4% -$1.12M 0.17% 129
2018
Q2
$27.1M Buy
169,911
+453
+0.3% +$69.1K 0.16% 142
2018
Q1
$23.3M Sell
169,458
-14,349
-8% -$2M 0.14% 157
2017
Q4
$22.4M Sell
183,807
-28,512
-13% -$3.57M 0.13% 181
2017
Q3
$24.7M Sell
212,319
-558
-0.3% -$60.8K 0.13% 177
2017
Q2
$22.1M Sell
212,877
-2,520
-1% -$242K 0.12% 191
2017
Q1
$18.3M Sell
215,397
-11,790
-5% -$931K 0.11% 214
2016
Q4
$16M Buy
227,187
+14,976
+7% +$1.1M 0.1% 229
2016
Q3
$17.1M Buy
212,211
+6,633
+3% +$508K 0.11% 224
2016
Q2
$15.1M Buy
205,578
+34,992
+21% +$2.46M 0.1% 227
2016
Q1
$11.4M Buy
170,586
+3,636
+2% +$225K 0.08% 259
2015
Q4
$10.1M Buy
166,950
+288
+0.2% +$16.2K 0.08% 281
2015
Q3
$8.51M Sell
166,662
-3,024
-2% -$171K 0.07% 303
2015
Q2
$9.13M Sell
169,686
-5,940
-3% -$332K 0.06% 323
2015
Q1
$9.86M Buy
175,626
+42,642
+32% +$2.41M 0.07% 337
2014
Q4
$7.82M Sell
132,984
-1,260
-0.9% -$70.2K 0.06% 360
2014
Q3
$6.89M Sell
134,244
-6,930
-5% -$344K 0.05% 388
2014
Q2
$6.46M Sell
141,174
-1,170
-0.8% -$51.6K 0.05% 424
2014
Q1
$6.93M Buy
142,344
+900
+0.6% +$42.4K 0.06% 364
2013
Q4
$6.04M Buy
141,444
+41,922
+42% +$1.76M 0.05% 396
2013
Q3
$4.16M Buy
99,522
+31,671
+47% +$1.4M 0.04% 467
2013
Q2
$3.82M Buy
+67,851
New +$3.74M 0.04% 425

Other funds holding ISRG

Aviva's ISRG Position: Q1 2026 in Review

Aviva increased its Intuitive Surgical (ISRG) stake by 2.9% in Q1 2026, buying an estimated $4.44M and bringing the position to 306,437 shares worth $141M. The position accounts for 0.24% of the portfolio, ranked #76.

Aviva first reported a position in ISRG in Q2 2013 and has held it in 52 quarters since. The position peaked at $169M in Q4 2025. 2,303 funds tracked by Wall St. Rank hold ISRG as of Q1 2026.

  • Aviva held 306,437 shares of Intuitive Surgical worth $141M as of Q1 2026.
  • Aviva bought 8,778 Intuitive Surgical shares in Q1 2026, an estimated $4.44M.
  • Intuitive Surgical made up 0.24% of Aviva's portfolio in Q1 2026, its #76 holding.
  • Aviva first reported a position in Intuitive Surgical in Q2 2013 and has held it in 52 quarters since.
  • Aviva's Intuitive Surgical position peaked at $169M in Q4 2025.
  • 2,303 funds tracked by Wall St. Rank held Intuitive Surgical as of Q1 2026.

Based on Aviva's 13F filing for Q1 2026, filed 14 May 2026.